What happened: MFII11 (a Brazilian REIT — Fundo de Investimento Imobiliário — focused on affordable residential development) fell 6.6% in 7 days and 21.0% in 30 days. The trigger was its non-core stake in MCEM11, a cemetery-related fund that now represents 22.75% of MFII11's net assets (R$ 149.9 million). MCEM11 suffered a governance collapse: distributions suspended through 2027, a failed capital raise (only 8.9% subscribed), and a shareholder vote to forcibly migrate all exchange-listed units to an OTC market — killing liquidity. On top of that, MFII11 had already cut its monthly payout from R$ 1.06 to R$ 0.91 in April.
Will the R$ 0.91 monthly payout fall further? Not in the near term. Management confirmed this level through the entire second quarter of 2026 (June's distribution paid July 14). Longer term, the risk is low-to-moderate: the annualized payout of R$ 10.92 runs 17% below the fund's own guidance of R$ 13.15/year, suggesting the current level is already a conservative, sustainable floor rather than an artificially propped number.
What to do: HOLD. The core residential development business (MCMV — Brazil's affordable housing program, Minha Casa Minha Vida) keeps operating normally. New Livus-brand projects are launching. Selling at R$ 51.91 with a 46% discount to NAV is locking in losses at near-worst-case prices.
MFII11 — Mérito Desenvolvimento Imobiliário I FII — became the most-discussed Brazilian REIT in the affordable-housing category during June 2026. The unit price slid from roughly R$ 71.73 at year-end 2025 to R$ 51.91 on June 29, a 27.7% decline year-to-date. A large portion of the damage happened in the last few weeks. This report answers, point by point, what a unit holder needs to know before acting.
What is MCEM11 — and how did it destroy value?
To understand MFII11's selloff, you need to understand MCEM11. It is a fund tied to municipal cemetery concessions in the state of São Paulo — an unrelated, exotic bet far from Mérito Investimentos' core business of MCMV residential development. MFII11 holds this position as a non-core asset, and it represents 22.75% of the fund's net assets, or approximately R$ 149.9 million.
What was once seen as a supplemental income stream collapsed into a liability chain throughout the second quarter of 2026. The sequence:
- Shareholder meeting (AGO) on May 22, 2026: 84.77% of MCEM11 unit holders voted to reject the 2025 financial statements — without officially stating a reason. A rejection of that scale is a severe governance red flag.
- Failed capital raise (8th issuance): MCEM11 managed to raise only 8.9% of the maximum planned. The market, in effect, boycotted the offering — leaving the fund without fresh capital.
- Extraordinary meeting (AGE) on June 8, 2026: approved the forced migration of 100% of MCEM11's exchange-listed (B3) units to an OTC (balcão organizado) market segment. This effectively eliminates the liquidity window for any seller — including MFII11.
- Distributions suspended through 2027: the São Paulo City Hall has not authorized billing of maintenance fees, freezing MCEM11's income stream — roughly R$ 8.04 per unit per year — indefinitely.
How much is locked up: R$ 149.9 million — 22.75% of MFII11's assets. If the OTC migration is finalized, exiting this position in the near term becomes practically impossible. And with MCEM11's distributions frozen, this slice of the portfolio generates zero income for MFII11 unit holders.
In effect, nearly a quarter of the fund became an illiquid, income-free asset with open governance questions. The market responded by repricing the entire MFII11 as if that portion were worth far less than book value — hence the 21% decline in 30 days.
The core business is still working
Here is the key distinction between a broken-fund thesis and an exaggerated-discount thesis: MFII11's principal business has not stopped. Mérito Investimentos brings 13 years of experience and deep specialization in MCMV — Brazil's federal subsidized housing program — and the Livus residential brand. That engine is still running.
The standout recent development is the Livus Oratório launch in May 2026: 190 units, gross development value exceeding R$ 61 million, located in the Vila Prudente neighborhood in São Paulo, with strong early sales velocity. This is the first of three planned Livus launches in 2026. Combined with 14 active construction sites and a land bank exceeding R$ 1.1 billion in GDV, the operational pipeline is solid.
Historical context matters: since its IPO, MFII11 has delivered +418.62%, equivalent to 159.01% of Brazil's CDI (the overnight interbank rate) over the same period. The manager knows how to operate a residential development cycle. What broke was an off-strategy appendage, not the fund's core.
Is the R$ 0.91 monthly distribution safe?
This is the most frequently asked question. The monthly payout was cut from R$ 1.06 to R$ 0.91 in April 2026 — a 14% reduction — driven by three specific factors:
- SPE Consórcio Cortel SP with negative cash flow: the 2026 projection shows -R$ 10.17 million, meaning this vehicle will require capital injections rather than generating returns this year.
- Construction cost inflation: petroleum-derived materials saw cost increases above 30%, compressing project margins.
- Lost MCEM11 income: with MCEM11's distribution suspended, the 22.75% of assets tied up there stopped contributing to MFII11's income pool — an indirect but real impact.
The positive side: the R$ 0.91 level is locked in through the full second quarter of 2026, with June's payment due July 14. The probability of another cut in the very near term is low. Medium-term risk is low to moderate — the annualized R$ 10.92 already runs 17% below the manager's own annual guidance of R$ 13.15, suggesting the payout was intentionally reset to a sustainable level, not propped up artificially.
Watch this trigger: if the monthly payout falls below R$ 0.75, the income thesis changes fundamentally — it would signal that Cortel's cash drain and MCEM11's income gap are eating into operating cash beyond what was initially modeled. Above that threshold, R$ 0.91 appears to be the floor.
Valuation: fair value and the real discount
The headline number is a P/NAV of 0.54×, a 46.3% discount to the book NAV per unit of R$ 96.60. Taking that book value at face value would be naive, however — the MCEM11 stake clearly does not belong in the balance sheet at full carrying value given the suspended income, governance crisis, and impending OTC migration.
A reasonable approach applies a haircut of approximately 15% to the MCEM11 allocation (22.75% of net assets). This reduces the effective NAV per unit by roughly R$ 3.30, yielding an adjusted NAV of approximately R$ 93.30. Adding a further risk discount — standard for development-stage REITs under Brazil's elevated Selic rate (the central bank benchmark), which compresses valuation multiples across the category — produces an estimated fair value around R$ 80.
At R$ 51.91, that implies approximately 54% upside to fair value before dividends. The scenario range:
| Scenario | Key assumption | Fair value | Upside |
|---|---|---|---|
| Bear | MCEM11 near-total loss; another DPS cut | ~R$ 60 | +16% |
| Base | MCEM11 at 15% haircut; DPS stable at R$ 0.91 | ~R$ 80 | +54% |
| Bull | MCEM11 resolution + Livus launches gain traction | ~R$ 95 | +83% |
Notice that even the bear scenario — assuming near-total loss on the MCEM11 position and a further distribution cut — still places fair value above the current price. That suggests the market has already priced in close to the worst case. Among comparable development-stage Brazilian REITs — TGAR11, HOSI11, and BIPD11 — MFII11 currently trades at one of the deepest discounts in the peer group.
Verdict: what should you do?
Score: 5.5/10
Verdict: HOLD
Bull case: deep P/NAV discount (0.54×), solid MCMV pipeline with 14 active sites and a R$ 1.1B land bank, Livus brand launches underway, and a discount that already embeds near-worst-case outcomes.
Bear case: R$ 149.9M effectively illiquid in MCEM11 with no near-term income, monthly distribution 17% below guidance, and SPE Cortel requiring capital injections throughout 2026.
If you already own it: hold. Wait for the MCEM11 resolution and for Livus project sales to accelerate. Selling at R$ 51.91 means crystallizing losses at a point where the adjusted discount is still historically large.
If you're considering entering: a small position makes sense only for investors with high risk tolerance, a 3+ year horizon, and the ability to withstand continued volatility. This is not a fund for predictable income.
Exit the thesis if: monthly DPS drops below R$ 0.75, OR the MCEM11 outcome proves worse than expected (total position loss with no recovery pathway through the OTC market).
The bottom line: MFII11 is not a broken fund, but it is not a risk-free bargain either. What the market did was reprice the whole entity because of a non-core position gone wrong. For existing holders, the right posture is to monitor the defined triggers and let the MCMV core do its work. For prospective buyers, entry requires full clarity on what you're purchasing: a real discount, yes — but with a real, visible risk attached to it.
